Immunotherapy Coverage From Every Angle
Advertisement
Advertisement

Recent News

ASCO-SITC 2019: HER2-Targeted Vaccine Plus Trastuzumab in Breast Cancer
Nivolumab in Metastatic Kidney Cancer in ‘Real-World Setting’
Trastuzumab Biosimilar for HER2-Overexpressing Breast Cancer Approved by the FDA
2019 ASCO-SITC: Tumor Growth Rate and Outcomes With Nivolumab in Head and Neck Cancer
2019 ASCO-SITC Symposium: Predicting Outcomes With Immunotherapy for Melanoma
FDA Grants Accelerated Approval to Atezolizumab Combination in Triple-Negative Breast Cancer
2019 ASCO-SITC Symposium: Neoadjuvant Atezolizumab in NSCLC
2019 ESMO TAT: Predicting Outcomes With Lung Immune Prognostic Index
2019 ASCO-SITC Symposium: Regulatory T Cells and Treatment Resistance in Head/Neck Cancer
FDA Approves New Formulation of Trastuzumab for Subcutaneous Use in Some Breast Cancers
2019 GU Symposium: Subgroup Analysis of Avelumab + Axitinib in JAVELIN Renal 101 Trial
2019 ASCO-SITC Symposium: Vaccine Plus Nivolumab in Lung Cancer
Novel Antibody-Drug Conjugates in Ovarian Cancer
Priority Review Granted to Pembrolizumab Combination in First-Line Therapy for Advanced Kidney Cancer
FDA Accepts for Priority Review Avelumab and Axitinib Combination for Advanced Kidney Cancer
2019 GU Symposium: Nivolumab Plus Ipilimumab in Metastatic Castration-Resistant Prostate Cancer
FDA Approves Pembrolizumab in Adjuvant Treatment of Melanoma
FDA Grants Priority Review to Pembrolizumab in First-Line Therapy for Metastatic Head/Neck Cancer
2019 GU Symposium: Pembrolizumab Plus Axitinib Versus Sunitinib in Advanced Kidney Cancer
Daratumumab Split-Dosing Regimen for Multiple Myeloma Approved by the FDA
2019 GI Symposium: New Phase II/III Trial of Nivolumab in Metastatic Colorectal Cancer
FDA Accepts sBLA for Atezolizumab Plus Chemotherapy in First-Line Treatment of Metastatic NSCLC
KEYNOTE-040 Supports Benefit of Pembrolizumab in Resistant Head and Neck Cancer
FDA Expands Pemetrexed Indication With Pembrolizumab and Chemotherapy in First-Line Treatment of NSCLC
2019 GI Symposium: Combination Immunotherapy for Refractory Colorectal Carcinoma
European Commission Approves Split-Dose of Daratumumab in Multiple Myeloma
Predicting Which Melanoma Tumors Will Respond to Checkpoint Immunotherapy


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.